Cargando…

Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy

BACKGROUND: Due to the invasiveness of prostate biopsy, a prediction model of the individual risk of a positive biopsy result could be helpful to guide clinical decision-making. Most existing models are based on transrectal ultrasonography (TRUS)-guided biopsy. On the other hand, transperineal templ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuliang, Zhou, Zhien, Zhou, Yi, Wu, Xingcheng, Xiao, Yu, Ji, Zhigang, Li, Hanzhong, Yan, Weigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063345/
https://www.ncbi.nlm.nih.gov/pubmed/33892696
http://dx.doi.org/10.1186/s12894-021-00840-5
_version_ 1783681936480272384
author Chen, Yuliang
Zhou, Zhien
Zhou, Yi
Wu, Xingcheng
Xiao, Yu
Ji, Zhigang
Li, Hanzhong
Yan, Weigang
author_facet Chen, Yuliang
Zhou, Zhien
Zhou, Yi
Wu, Xingcheng
Xiao, Yu
Ji, Zhigang
Li, Hanzhong
Yan, Weigang
author_sort Chen, Yuliang
collection PubMed
description BACKGROUND: Due to the invasiveness of prostate biopsy, a prediction model of the individual risk of a positive biopsy result could be helpful to guide clinical decision-making. Most existing models are based on transrectal ultrasonography (TRUS)-guided biopsy. On the other hand, transperineal template-guided prostate biopsy (TTPB) has been reported to be more accurate in evaluating prostate cancer. The objective of this study is to develop a prediction model of the detection of high-grade prostate cancer (HGPC) on initial TTPB. RESULT: A total of 1352 out of 3794 (35.6%) patients were diagnosed with prostate cancer, 848 of whom had tumour with Grade Group 2–5. Age, PSA, PV, DRE and f/t PSA are independent predictors of HGPC with p < 0.001. The model showed good discrimination ability (c-index 0.886) and calibration during internal validation and good clinical performance was observed through decision curve analysis. The external validation of CPCC-RC, an existing model, demonstrated that models based on TRUS-guided biopsy may underestimate the risk of HGPC in patients who underwent TTPB. CONCLUSION: We established a prediction model which showed good discrimination ability and calibration in predicting the detection of HGPC by initial TTPB. This model can be used to aid clinical decision making for Chinese patients and other Asian populations with similar genomic backgrounds, after external validations are conducted to further confirm its clinical applicability.
format Online
Article
Text
id pubmed-8063345
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80633452021-04-23 Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy Chen, Yuliang Zhou, Zhien Zhou, Yi Wu, Xingcheng Xiao, Yu Ji, Zhigang Li, Hanzhong Yan, Weigang BMC Urol Research BACKGROUND: Due to the invasiveness of prostate biopsy, a prediction model of the individual risk of a positive biopsy result could be helpful to guide clinical decision-making. Most existing models are based on transrectal ultrasonography (TRUS)-guided biopsy. On the other hand, transperineal template-guided prostate biopsy (TTPB) has been reported to be more accurate in evaluating prostate cancer. The objective of this study is to develop a prediction model of the detection of high-grade prostate cancer (HGPC) on initial TTPB. RESULT: A total of 1352 out of 3794 (35.6%) patients were diagnosed with prostate cancer, 848 of whom had tumour with Grade Group 2–5. Age, PSA, PV, DRE and f/t PSA are independent predictors of HGPC with p < 0.001. The model showed good discrimination ability (c-index 0.886) and calibration during internal validation and good clinical performance was observed through decision curve analysis. The external validation of CPCC-RC, an existing model, demonstrated that models based on TRUS-guided biopsy may underestimate the risk of HGPC in patients who underwent TTPB. CONCLUSION: We established a prediction model which showed good discrimination ability and calibration in predicting the detection of HGPC by initial TTPB. This model can be used to aid clinical decision making for Chinese patients and other Asian populations with similar genomic backgrounds, after external validations are conducted to further confirm its clinical applicability. BioMed Central 2021-04-23 /pmc/articles/PMC8063345/ /pubmed/33892696 http://dx.doi.org/10.1186/s12894-021-00840-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Yuliang
Zhou, Zhien
Zhou, Yi
Wu, Xingcheng
Xiao, Yu
Ji, Zhigang
Li, Hanzhong
Yan, Weigang
Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title_full Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title_fullStr Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title_full_unstemmed Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title_short Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
title_sort development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063345/
https://www.ncbi.nlm.nih.gov/pubmed/33892696
http://dx.doi.org/10.1186/s12894-021-00840-5
work_keys_str_mv AT chenyuliang developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT zhouzhien developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT zhouyi developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT wuxingcheng developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT xiaoyu developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT jizhigang developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT lihanzhong developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy
AT yanweigang developmentandinternalvalidationofapredictionmodelofprostatecanceroninitialtransperinealtemplateguidedprostatebiopsy